Nature Reviews Immunology 11, 865–872 (2011)
On page 872 of the original version of this article, under the subheading “New vaccine development technologies”, there was an error in the sentence that began: “AS04 (GlaxoSmithKline), an adjuvant composed of aluminium salt and the Toll-like receptor (TLR) against MPL”. This sentence should begin: “AS04 (GlaxoSmithKline), an adjuvant composed of aluminium salt and the Toll-like receptor (TLR) agonist MPL”. The authors apologize for this error.
Additional information
The online version of the original article can be found at 10.1038/nri3085
Rights and permissions
About this article
Cite this article
Rappuoli, R., Mandl, C., Black, S. et al. Erratum: Vaccines for the twenty-first century society. Nat Rev Immunol 12, 225 (2012). https://doi.org/10.1038/nri3168
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri3168
